Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.
Actively Recruiting
Researchers are evaluating the efficacy and safety of FT819, a treatment made of allogeneic T cells expressing a CD19-targeted CAR, for people with moderate-to-severe systemic lupus erythematosus SLE who have lupus nephritis LN that has not responded to at least two prior immunosuppressive treatments. This phase 2, open-label, single-arm trial focuses on participants aged 12 to 70 with biopsy-proven Class III or IV LN and active disease. The study aims to measure how many participants achieve complete renal response at 26 weeks. Participants will first undergo a screening period lasting up to 28 days. After screening, they will receive bendamustine treatment followed by a single intravenous infusion of FT819. The study will include efficacy, safety, and exploratory assessments at scheduled timepoints through 24 months of post-treatment follow-up. After this, participants will be monitored for safety and survival for up to 15 years in a long-term follow-up phase. Throughout the study, researchers will assess lupus nephritis activity using standard measures, including complete and partial renal responses, and clinician-reported outcomes such as SLEDAI-2K, BILAG, and PGA scores. Safety and disease activity evaluations will take place at predefined visits. The total duration of participation includes multiple assessments during the first two years and extended long-term monitoring up to 15 years to observe ongoing effects and survival.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.
Actively Recruiting
Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, and how the body processes LY4213663 in healthy adults and adults with rheumatoid arthritis RA. This Phase 1 study aims to understand potential side effects and how the drug behaves when given by injection under the skin or into a vein. The study includes both healthy participants and those diagnosed with RA, with a focus on basic science aspects of the treatment. The study involves several parts single-ascending doses a gradually increasing dose and multiple-ascending doses of LY4213663 or placebo given either subcutaneously or intravenously in healthy participants. In participants with RA, multiple doses of LY4213663 are given by these two methods. The study design includes randomized assignments to drug or placebo groups for the healthy participant parts, while the RA participant parts are open-label. The entire study lasts about 33 weeks, excluding screening. Participants will have blood tests to check drug levels and effects, as well as monitoring for any serious side effects related to the drug. Researchers will assess safety throughout the study by tracking adverse events. The study measures how much LY4213663 is in the blood over time and its maximum concentration. Participants will attend regular visits for dosing and assessments during the study period, which runs from screening through to the last follow-up around 33 weeks after dosing begins.
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.
Actively Recruiting
Researchers are conducting a multicenter, randomized, double-blind Phase 2 study to evaluate the pharmacodynamics, safety, and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484 alone, inclisiran alone, and placebo in adults with hypertension and hypercholesterolemia. The study focuses on understanding how these treatments affect certain blood markers and blood pressure in this population. Participants receive a single dose of either the combination of QCZ484 and inclisiran, QCZ484 alone, inclisiran alone, or placebo on Day 1. The study lasts up to 12 months and includes a screening period with two visits to confirm eligibility, followed by the treatment administration at the baselinerandomization visit. After treatment, participants enter a safety follow-up phase, with an option to join an open-label extension study instead of the follow-up. During the study, participants undergo various assessments including measurements of PCSK9 and AGT levels at baseline and Month 3, blood pressure and LDL cholesterol levels at baseline, Month 3, and Month 6, along with monitoring for treatment-emergent adverse events and changes in laboratory tests and vital signs for up to 12 months. These evaluations help researchers understand the effects and safety of the treatments over time.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.
Actively Recruiting
Researchers are evaluating telitacicept, a recombinant fusion protein targeting B-cell pathways, in adults with active primary Sjogrens disease. This phase 3 trial explores telitacicepts potential to reduce B-cell activity and autoimmune effects contributing to disease symptoms. The study compares telitacicept with a placebo to assess its impact on disease activity and patient well-being. Participants are randomly assigned to receive either telitacicept or placebo via subcutaneous injection. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The primary treatment period lasts 48 weeks, during which the effects on disease activity and gland function are evaluated. Throughout the study, participants undergo assessments including the EULAR Sjogrens Syndrome Disease Activity Index ESSDAI, patient and physician disease activity evaluations, fatigue assessment, and gland function tests. Safety and efficacy are monitored regularly, with the primary outcome measured at Week 48. The total study duration extends until January 2029, allowing comprehensive evaluation of telitacicepts effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tafasitamab INCA000585 in adults who have primary autoimmune blood cell disorders, including primary immune thrombocytopenia ITP and primary warm autoimmune hemolytic anemia wAIHA. This is a Phase 2a, open-label, multicenter clinical trial focusing on treatment outcomes in these patients. Participants will receive intravenous infusions of tafasitamab at scheduled times as defined by the study protocol. The trial includes two experimental cohorts based on the specific autoimmune disorder one for primary ITP and another for primary wAIHA. The study will assess treatment effects up to 52 weeks, including response rates and duration of response. Throughout the study, participants will be monitored regularly for safety and treatment response. Assessments include tracking adverse events, platelet counts, hemoglobin levels, and serum concentrations of the study drug. Researchers will evaluate stable platelet and hemoglobin responses after Day 56 through Week 48, along with complete and partial remission rates at Weeks 24 and 48. The total participation may last up to approximately one year with ongoing evaluations to understand treatment impact and safety.